Literature DB >> 320727

Prepatent periods of a tropical strain of Plasmodium vivax after inoculations of tenfold dilutions of sporozoites.

E Ungureanu, R Killick-Kendrick, P C Garnham, P Branzei, C Romanescu, P G Shute.   

Abstract

Eleven patients requiring malaria therapy were inoculated intradermally with graded doses of sporozoites of the Chesson strain of Plasmodium vivax. Estimated doses of 10 sporozoites were given to four patients, of 100 to three patients, of 1,000 to two patients, and of 10,000 to two patients. Parasitaemia was detected in all patients 12 to 17 days after inoculation; fever began on the 14th to 19th days. The results of the trials are compared with earlier work on a temperate strain of P. vivax in which patients given small doses of sporozoites exhibited long prepatent periods of 257 days or more. It is concluded that the differences in the two strains can be explained by the assumption that, in varying proportions, all strains of P. vivax produce two types of sporozoites, one eliciting short prepatent periods (Type I), and the other lying dormant or developing slowly to give rise to long prepatent periods (Type II). The latter type greatly predominates in temperate strains, but not in tropical strains; at high dilutions, therefore, pure suspensions of Type II sporozoites of temperate strains can be prepared. It is thought that relapses of P. vivax are in reality a dalyed parasitaemia arising from Type II sporozoites.

Entities:  

Mesh:

Year:  1976        PMID: 320727     DOI: 10.1016/0035-9203(76)90133-4

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  18 in total

1.  The painstaking discovery of the hidden face of the human plasmodia.

Authors:  Jean-François Pays
Journal:  Parasitol Res       Date:  2012-05-18       Impact factor: 2.289

Review 2.  Cell invasion by the vertebrate stages of Plasmodium.

Authors:  P Sinnis; B K Sim
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

3.  Transgenic Anopheles stephensi coexpressing single-chain antibodies resist Plasmodium falciparum development.

Authors:  Alison T Isaacs; Nijole Jasinskiene; Mikhail Tretiakov; Isabelle Thiery; Agnès Zettor; Catherine Bourgouin; Anthony A James
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

4.  Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.

Authors:  Rie Takeuchi; Saranath Lawpoolsri; Mallika Imwong; Jun Kobayashi; Jaranit Kaewkungwal; Sasithon Pukrittayakamee; Supalap Puangsa-art; Nipon Thanyavanich; Wanchai Maneeboonyang; Nicholas P J Day; Pratap Singhasivanon
Journal:  Malar J       Date:  2010-11-01       Impact factor: 2.979

Review 5.  The hypnozoite and relapse in primate malaria.

Authors:  F B Cogswell
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

6.  Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection.

Authors:  Mehdi Labaied; Anke Harupa; Ronald F Dumpit; Isabelle Coppens; Sebastian A Mikolajczak; Stefan H I Kappe
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

7.  Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence.

Authors:  Kenneth J Longmuir; Richard T Robertson; Sherry M Haynes; Janie L Baratta; Alan J Waring
Journal:  Pharm Res       Date:  2006-03-24       Impact factor: 4.200

8.  Engineered resistance to Plasmodium falciparum development in transgenic Anopheles stephensi.

Authors:  Alison T Isaacs; Fengwu Li; Nijole Jasinskiene; Xiaoguang Chen; Xavier Nirmala; Osvaldo Marinotti; Joseph M Vinetz; Anthony A James
Journal:  PLoS Pathog       Date:  2011-04-21       Impact factor: 6.823

Review 9.  Determinants of relapse periodicity in Plasmodium vivax malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2011-10-11       Impact factor: 2.979

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.